Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2

David S. Geller, Michael Y. Singh, Wendong Zhang, Jonathan Gill, Michael E. Roth, Mimi Kim, Xianhong Xie, Christopher K. Singh, Howard D. Dorfman, Esperanza Villanueva-Siles, Amy Park, Sajida Piperdi, Richard Gorlick

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: It is increasingly relevant to better define what constitutes an adequate surgical margin in an effort to improve reconstructive longevity and functional outcomes following osteosarcoma surgery. In addition, nonunion remains a challenging problem in some patients following allograft reconstruction. Bone morphogenetic protein-2 (BMP-2) could enhance osseous union, but has been historically avoided due to concerns that it may promote tumor recurrence. Experimental Design: An orthotopic xenograft murine model was utilized to describe the natural temporal course of osteosarcoma growth. Tumors were treated either with surgery alone, surgery and single-agent chemotherapy, or surgery and dual-agent chemotherapy to assess the relationship between surgical margin and local recurrence. The effect of BMP-2 on local recurrence was similarly assessed. Results: Osteosarcoma tumor growth was categorized into reproducible phases. Margins greater than 997 um resulted in local control following surgery alone. Margins greater than 36 um resulted in local control following surgery and single-agent chemotherapy. Margins greater than 12 (xm resulted in local control following surgery and dual-agent chemotherapy. The application of exogenous BMP-2 does not confer an increased risk of local recurrence. Conclusions: This model reliably reproduces the clinical, radiographic, and surgical conditions encountered in human osteosarcoma. It successfully incorporates relevant chemotherapy, further paralleling the human experience. Surgical margins required to achieve local control in osteosarcoma can be reduced using single-agent chemotherapy and further decreased using dual-agent chemotherapy. The application of BMP-2 does not increase local recurrence in this model.

Original languageEnglish (US)
Pages (from-to)3003-3012
Number of pages10
JournalClinical Cancer Research
Volume21
Issue number13
DOIs
StatePublished - Jul 1 2015

Fingerprint

Bone Morphogenetic Protein 2
Osteosarcoma
Recurrence
Drug Therapy
Growth
Heterografts
Allografts
Neoplasms
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2. / Geller, David S.; Singh, Michael Y.; Zhang, Wendong; Gill, Jonathan; Roth, Michael E.; Kim, Mimi; Xie, Xianhong; Singh, Christopher K.; Dorfman, Howard D.; Villanueva-Siles, Esperanza; Park, Amy; Piperdi, Sajida; Gorlick, Richard.

In: Clinical Cancer Research, Vol. 21, No. 13, 01.07.2015, p. 3003-3012.

Research output: Contribution to journalArticle

Geller, David S. ; Singh, Michael Y. ; Zhang, Wendong ; Gill, Jonathan ; Roth, Michael E. ; Kim, Mimi ; Xie, Xianhong ; Singh, Christopher K. ; Dorfman, Howard D. ; Villanueva-Siles, Esperanza ; Park, Amy ; Piperdi, Sajida ; Gorlick, Richard. / Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 13. pp. 3003-3012.
@article{74830ab4dfce48a4b833cc5c1e083c4c,
title = "Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2",
abstract = "Purpose: It is increasingly relevant to better define what constitutes an adequate surgical margin in an effort to improve reconstructive longevity and functional outcomes following osteosarcoma surgery. In addition, nonunion remains a challenging problem in some patients following allograft reconstruction. Bone morphogenetic protein-2 (BMP-2) could enhance osseous union, but has been historically avoided due to concerns that it may promote tumor recurrence. Experimental Design: An orthotopic xenograft murine model was utilized to describe the natural temporal course of osteosarcoma growth. Tumors were treated either with surgery alone, surgery and single-agent chemotherapy, or surgery and dual-agent chemotherapy to assess the relationship between surgical margin and local recurrence. The effect of BMP-2 on local recurrence was similarly assessed. Results: Osteosarcoma tumor growth was categorized into reproducible phases. Margins greater than 997 um resulted in local control following surgery alone. Margins greater than 36 um resulted in local control following surgery and single-agent chemotherapy. Margins greater than 12 (xm resulted in local control following surgery and dual-agent chemotherapy. The application of exogenous BMP-2 does not confer an increased risk of local recurrence. Conclusions: This model reliably reproduces the clinical, radiographic, and surgical conditions encountered in human osteosarcoma. It successfully incorporates relevant chemotherapy, further paralleling the human experience. Surgical margins required to achieve local control in osteosarcoma can be reduced using single-agent chemotherapy and further decreased using dual-agent chemotherapy. The application of BMP-2 does not increase local recurrence in this model.",
author = "Geller, {David S.} and Singh, {Michael Y.} and Wendong Zhang and Jonathan Gill and Roth, {Michael E.} and Mimi Kim and Xianhong Xie and Singh, {Christopher K.} and Dorfman, {Howard D.} and Esperanza Villanueva-Siles and Amy Park and Sajida Piperdi and Richard Gorlick",
year = "2015",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-14-0986",
language = "English (US)",
volume = "21",
pages = "3003--3012",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Development of a model system to evaluate local recurrence in osteosarcoma and assessment of the effects of bone morphogenetic protein-2

AU - Geller, David S.

AU - Singh, Michael Y.

AU - Zhang, Wendong

AU - Gill, Jonathan

AU - Roth, Michael E.

AU - Kim, Mimi

AU - Xie, Xianhong

AU - Singh, Christopher K.

AU - Dorfman, Howard D.

AU - Villanueva-Siles, Esperanza

AU - Park, Amy

AU - Piperdi, Sajida

AU - Gorlick, Richard

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose: It is increasingly relevant to better define what constitutes an adequate surgical margin in an effort to improve reconstructive longevity and functional outcomes following osteosarcoma surgery. In addition, nonunion remains a challenging problem in some patients following allograft reconstruction. Bone morphogenetic protein-2 (BMP-2) could enhance osseous union, but has been historically avoided due to concerns that it may promote tumor recurrence. Experimental Design: An orthotopic xenograft murine model was utilized to describe the natural temporal course of osteosarcoma growth. Tumors were treated either with surgery alone, surgery and single-agent chemotherapy, or surgery and dual-agent chemotherapy to assess the relationship between surgical margin and local recurrence. The effect of BMP-2 on local recurrence was similarly assessed. Results: Osteosarcoma tumor growth was categorized into reproducible phases. Margins greater than 997 um resulted in local control following surgery alone. Margins greater than 36 um resulted in local control following surgery and single-agent chemotherapy. Margins greater than 12 (xm resulted in local control following surgery and dual-agent chemotherapy. The application of exogenous BMP-2 does not confer an increased risk of local recurrence. Conclusions: This model reliably reproduces the clinical, radiographic, and surgical conditions encountered in human osteosarcoma. It successfully incorporates relevant chemotherapy, further paralleling the human experience. Surgical margins required to achieve local control in osteosarcoma can be reduced using single-agent chemotherapy and further decreased using dual-agent chemotherapy. The application of BMP-2 does not increase local recurrence in this model.

AB - Purpose: It is increasingly relevant to better define what constitutes an adequate surgical margin in an effort to improve reconstructive longevity and functional outcomes following osteosarcoma surgery. In addition, nonunion remains a challenging problem in some patients following allograft reconstruction. Bone morphogenetic protein-2 (BMP-2) could enhance osseous union, but has been historically avoided due to concerns that it may promote tumor recurrence. Experimental Design: An orthotopic xenograft murine model was utilized to describe the natural temporal course of osteosarcoma growth. Tumors were treated either with surgery alone, surgery and single-agent chemotherapy, or surgery and dual-agent chemotherapy to assess the relationship between surgical margin and local recurrence. The effect of BMP-2 on local recurrence was similarly assessed. Results: Osteosarcoma tumor growth was categorized into reproducible phases. Margins greater than 997 um resulted in local control following surgery alone. Margins greater than 36 um resulted in local control following surgery and single-agent chemotherapy. Margins greater than 12 (xm resulted in local control following surgery and dual-agent chemotherapy. The application of exogenous BMP-2 does not confer an increased risk of local recurrence. Conclusions: This model reliably reproduces the clinical, radiographic, and surgical conditions encountered in human osteosarcoma. It successfully incorporates relevant chemotherapy, further paralleling the human experience. Surgical margins required to achieve local control in osteosarcoma can be reduced using single-agent chemotherapy and further decreased using dual-agent chemotherapy. The application of BMP-2 does not increase local recurrence in this model.

UR - http://www.scopus.com/inward/record.url?scp=84941966978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941966978&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0986

DO - 10.1158/1078-0432.CCR-14-0986

M3 - Article

C2 - 25472999

AN - SCOPUS:84941966978

VL - 21

SP - 3003

EP - 3012

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -